MedLife S.A.

Transaction in Own Shares • Jul 7, 2025

No. 58 / 7 July 2025

To: BUCHAREST STOCK EXCHANGE FINANCIAL SUPERVISORY AUTHORITY

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations and Law no. 24/2017 on issuers of financial instruments and market operations

Report Date: 7 July 2025 Name of the issuing company: MED LIFE S.A. ("MedLife" or "the Company") Registered Office: Bucharest, 365 Calea Grivitei, district 1, Romania Telephone / Fax number: 0374 180 470 Unique Registration Code at the National Office of Trade Registry: 8422035 Order number on the Trade Registry: J1996003709402 EUID: ROONRC.J1996003709402 Subscribed and paid-in share capital: 132,870,492 RON Total number of shares: 531,481,968 (out of which 665,983 shares without voting rights and 530,815,985 shares with voting rights) Regulated market on which the issued securities are traded: Bucharest Stock Exchange, Premium Category

Significant events to report:

In accordance with ASF Regulation no. 5/2018 and art. 2 of the Commission Delegated Regulation (EU) 1052/2016, MED LIFE S.A. reports to the regulated market the following transactions performed for M symbol during 30 June – 4 July 2025:

Intermediary of transactions: BT Capital Partners S.A.

Reason for the notification of the transactions: buy-back of MedLife own ordinary shares in accordance with EGSM Decision no. 2 from 21 November 2024.

Summary of transactions during 30 June – 4 July 2025:

Transaction Date	Nature of transaction	Trading place	Aggregate volume	Weighted average price/share (RON)	Value (RON)
06-30-25	Buy-Back	Regulated market	-	-	-
07-01-25	Buy-Back	Regulated market	-	-	-
07-02-25	Buy-Back	Regulated market	-	-	-
07-03-25	Buy-Back	Regulated market	-	-	-
07-04-25	Buy-Back	Regulated market	-	-	-
Total			-	-	-

Detailed transactions for the 30 June – 4 July 2025 period:

No share buy-back transactions were performed during 30 June – 4 July 2025.

Mihail Marcu Chief Executive Officer

________________